Bausch Health’s Solta unit and closely held Sciton agreed to settle a lawsuit in which Bausch had accused Sciton’s aesthetic products of infringing two patents related to laser-treatment technologies for skin care.
- No details of the July 15 settlement were provided in the agreement, filed July 19 but not yet approved in federal court in Wilmington, Delaware
- Sciton products targeted in the complaint included Halo hybrid fractional laser and ProFractional
- Solta’s products include Fraxel and Clear+Brilliant, laser treatments that help prevent visible signs of aging, according to complaint
- NOTE: Bausch’s Solta Sues Sciton for Laser-Treatment Patent Royalties
- CASE: Solta ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.